Market Overview

Morgan Stanley Sees Growth Platforms Building for Stericycle

Related SRCL
Stericycle Announces Settlement to End 7-Year Qui Tam Suit
Stericycle Prices Public Offering of Mandatory Convertible Preferred Stock at $100/Depositary Share

In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Stericycle (NASDAQ: SRCL).

In the report, Morgan Stanley noted, “Organic revenue growth in 4Q13 ticked up slightly versus 3Q13 but remains consistent with 2012-13 trends. Greater traction from StrongPak is a modest positive but drove margin dilution. Full valuation and limited visibility on sustainable growth acceleration keeps us from a more constructive view.”

Stericycle closed on Wednesday at $116.48.

Latest Ratings for SRCL

May 2015Stifel NicolausMaintainsBuy
Mar 2015Imperial CapitalInitiates Coverage onIn-line
Nov 2014Bank of AmericaMaintainsBuy

View More Analyst Ratings for SRCL
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings


Related Articles (SRCL)

View Comments and Join the Discussion!

Get Benzinga's Newsletters